Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma

Journal of Postgraduate Medicine

Volumn 58, Issue 3, 2012, Pages 203-206

  Nandha, R ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

17 hydroxylase and c17; 20 lyase inhibitors; abiraterone acetate; castration resistant prostate carcinoma

Indexed keywords

ABIRATERONE ACETATE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICALUTAMIDE; DEXAMETHASONE; DIURETIC AGENT; DOCETAXEL; ENZALUTAMIDE; EPLERENONE; FLUTAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; NILUTAMIDE; PLACEBO; PREDNISOLONE;

ADRENAL INSUFFICIENCY; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHMA; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FLUID RETENTION; HEADACHE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; LIVER FUNCTION TEST; MIGRAINE; NAUSEA; PAIN; PATHOGENESIS; PERIPHERAL EDEMA; REVIEW; SIDE EFFECT; VOMITING;

ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTINEOPLASTIC AGENTS; CASTRATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84867298247     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.101400     Document Type: Review

References (25)

1. Kohli M, Tindall DJ. New Developments in the Medical Management of Prostate Cancer. Mayo Clin Proc 2010;85:77-86.
2. Nabhan C, Parsons B, Touloukian EZ, Stadler WM. Novel approaches and future directions in castration-resistant prostate cancer. Ann Oncol 2011;22:1948-57.
3. Moy B, Lee RJ, Smith M. Natural Products in Cancer Chemotherapy: Hormones and Related agents. In: Brunton L, editor. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill publishers; 2011. p. 1755-69.
4. Sharifi N, Gulley JL, Dahul WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17:305-15.
5. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
6. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw 2010;8:211-23.
7. Dawson NA, Ryan CJ. Abiraterone and newer antiandrogen compounds for castrate resistant metastatic prostate cancer. Br J Cancer 2009;100:671-5.
8. Tolcher AW, Cooper J. Castration-resistant prostate cancer: Hormone therapy redux. J Clin Oncol 2010;28:1447-9.
9. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:597-610.
10. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrationresisitant prostate cancer. J Clin Oncol 2010;28:1496-501.
11. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TA, et al. Increased Expression Of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer. Cancer Res 2006;66:2815-25.
12. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164:217-27.
13. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, et al. The Androgen Axis in Recurrent Prostate Cancer. Clin Cancer Res 2004;10:440-8.
14. Montgomery RB, Mostaghel EA, Vessela R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism in Castration-Resistant Tumor Growth. Cancer Res 2008;68:4447-54.
15. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: Established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8:449-57.
16. Mostaghel EA, Marck B, Plymate S, Vessella RL, Balk SP, Matsumoto AM, et al. Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants. Clin Cancer Res 2011;17:5913-25.
17. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17alpha-hydroxylase/C (17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.
18. Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G. Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer. Future Oncol 2010;6:665-79.
19. Ratain MK. Flushing Oral Oncology Drugs Down the Toilet. J Clin Oncol 2011;29:3958-9.
20. Jain RK, Brar SS, Lesko LJ. Food and oral antineoplastics: More than meets the eye. Clin Cancer Res 2010;16:4305-7.
21. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71.
22. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-8.
23. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8
24. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, et al. Significant and sustained antitumour activity in post-docetaxel, castration-resisitant prostaste cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95.
25. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med 2011;364:1995-2005.